Dr. Frederick K. Askari, MD, PHD
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Js Weill Medical College, Cornell University (1987)
- Years since graduation
- 39
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 182
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1987Medical school: Js Weill Medical College, Cornell University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MI license 4301051394 -
Clinical Molecular Genetics Physician
MI license 4301051394
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Michigan Health System Ann Arbor, MI
- Bronson Methodist Hospital Kalamazoo, MI
- Bronson Battle Creek Hospital Battle Creek, MI
- Henry Ford Allegiance Health Jackson, MI
- Mymichigan Medical Center Clare Clare, MI
Medical groups
- Regents of the University of Michigan (3,346 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 182
- Services billed
- 384
- Patients’ average age
- 66
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 118 | 40 |
| Established patient office or other outpatient visit, 40-54 minutes | 98 | 74 |
| Established patient office or other outpatient visit, 30-39 minutes | 52 | 46 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 17 |
| Biopsy of large bowel using a flexible endoscope | 15 | 15 |
| New patient office or other outpatient visit, 60-74 minutes | 14 | 14 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 14 | 14 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 13 | 13 |
| Hospital discharge day management, 30 minutes or less | 13 | 13 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 13 | 13 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ursodiol Other prescribers in Ann Arbor, MI | 180 |
| Tacrolimus Other prescribers in Ann Arbor, MI | 127 |
| Prednisone Other prescribers in Ann Arbor, MI | 102 |
| Xifaxan (rifaximin) Other prescribers in Ann Arbor, MI | 91 |
| Cyclosporine Modified (cyclosporine, modified) | 69 |
| Spironolactone Other prescribers in Ann Arbor, MI | 68 |
| Furosemide Other prescribers in Ann Arbor, MI | 54 |
| Omeprazole Other prescribers in Ann Arbor, MI | 36 |
| Entecavir | 34 |
| Envarsus Xr (tacrolimus) Other prescribers in Ann Arbor, MI | 30 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $75.03 in total to this clinician.
| Orphalan Inc | $75.03 |
|---|
| Food and Beverage | $75.03 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $104,429 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease
Ultragenyx Pharmaceutical Inc. · Active, not recruiting · NCT04884815
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.